FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023
AFT Pharma reports growth and global expansion
Read More
News
AFT welcomes US FDA approval for sale of Maxigesic IV®
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.
Read More
AFT Pharmaceuticals to announce half year interim results
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.
Read More
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read More
Retirement of Jon Lamb
Independent director Jon Lamb today retired from the board following his announcement at the ASM.
Read More
AFT Orphan Pharmaceuticals judgment
AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
Read More
AFT Pharma reports growth and global expansion
FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023
Read More
AFT welcomes US FDA approval for sale of Maxigesic IV®
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.
Read More
AFT Pharmaceuticals to announce half year interim results
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.
Read More
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read More
Retirement of Jon Lamb
Independent director Jon Lamb today retired from the board following his announcement at the ASM.
Read More
Retirement of Jon Lamb Announcement
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board. Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service […]
Read More
Notice of Annual Meeting of Shareholders 2023
June 30th 2023 Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on Friday, 4 August 2023 commencing at 10.30am (New Zealand time). Agenda A) Addresses Our Chairman, David Flacks, and […]
Read More
Financial Results 2023: AFT declares maiden dividend; record revenue
Financial Results for the 12 Months to 31st of March 2023
Read More
AFT Pharmaceuticals to announce full year results on Monday May 22 2023
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023.
Read More
US FDA sets PDUFA date for Maxigesic IV®
AFT Pharmaceuticals today announces the US Food and Drug Administration has set 17 October 2023 as the date by which it expects to respond to AFT’s application to register Maxigesic IV in the US.
Read More